Mr. Ehsan Agahi reports

ILLUMISOFT APPOINTS FORMER WHITE HOUSE CHIEF HEALTHCARE ECONOMIST JONATHAN KETCHAM AS STRATEGIC ADVISOR

Illumisoft Lighting Corp. has appointed Dr. Jonathan Ketcham as a strategic adviser to the company.

Dr. Ketcham brings deep expertise in health care economics, public policy, reimbursement, procurement and technology adoption. His guidance is expected to benefit Illumisoft greatly as it advances its ultraviolet germicidal technology platform toward commercialization across a range of applications.

Dr. Ketcham is the Earl G. and Gladys C. Davis distinguished research professor of economics at Arizona State University's W.P. Carey School of Business. As founder of Margin Health, he helps health care innovators navigate the regulatory, reimbursement and adoption pathways required to bring new technologies into commercial deployment.

From 2025 to 2026, Dr. Ketcham served as chief health care economist at the White House, advising on health care policy across the executive branch. His research applies causal inference methods to survey, experimental and real-world data to examine how incentives, information and institutional design shape decisions by payers, providers and patients. He has led multiple R01 grants and published widely across economics, medicine and health policy. He previously served as principal economist at Amazon and holds a PhD in economics from the Wharton School.

Management commentary

"Jonathan understands something that is critically important for Illumisoft: Great technology only creates value if it can be adopted in the real world," said Ehsan Agahi, executive chairman of Illumisoft. "His experience spanning the White House, academia, Amazon and health care economics gives him a unique perspective on how new technologies move through policy, procurement, reimbursement and institutional decision making. That perspective is exactly what we want at the table as we scale Illumisoft."

"From the first time I met this team, I've been excited about the chance to support them," said Dr. Ketcham. "They are committed to developing life-changing, life-saving technology, and my role is to help it reach as many people as possible, as fast as possible. The power of light to prevent disease is not just a beautiful metaphor, it's cutting-edge science. And it can protect all of us, everywhere."

Strategic importance

Illumisoft is advancing a platform of ultraviolet germicidal technologies designed to reduce airborne pathogen risk in occupied indoor environments. As the company moves its SaniLume and SaniLux platforms toward broader health care, government and institutional deployment, management believes that adoption will depend on more than product performance alone. It will require a clear understanding of health care economics, procurement pathways, policy priorities and the practical realities that shape how large institutions evaluate and adopt new technologies.

Dr. Ketcham's appointment strengthens Illumisoft's ability to position its technologies for real-world adoption in markets where infection prevention, indoor air quality and operational resilience are becoming increasingly important priorities.

Stock option issuance

The company has further announced that its board of directors has approved a grant of 875,000 stock options to certain officers, employees and consultants pursuant to the terms of the company's omnibus equity incentive plan.

The options have a grant date of June 25, 2026, and are each exercisable for one common share of the company at exercise price of 79 cents per common share, being the closing trading price of the company's shares on the TSX Venture Exchange on June 24, 2026. The options expire five years from the date of grant.

Three hundred thousand of the options vest as to 25 per cent after six months from the date of grant and the remainder in equal quarterly amounts over the following 18 months. The remainder of the options vest as to 25 per cent after six months from the date of grant and the remainder in equal quarterly amounts over the following 24 months.

The grant of the options are subject to the approval of the TSX-V. All of the options and any common shares issued on the exercise thereof are subject to a statutory hold period of four months and one day from the date of grant.

About Illumisoft Lighting Corp.

Illumisoft Lighting designs, develops and commercializes advanced ultraviolet germicidal solutions for health care, commercial, transportation, hospitality and other built environment markets. Its portfolio includes SaniLume upper-room germicidal UV (ultraviolet) and SaniLux 216-nanometre far UVC.

We seek Safe Harbor.